Aimmune to Present Full Phase 3 AR101 Data

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will present AR101 and patient quality of life data at the European Academy of Allergy and Clinical Immunology (EAACI) 2019 Congress, taking place June 1 to 5, 2019, in Lisbon, Portugal. Of the six abstracts accepted by EAACI, three are oral presentations and one is a late-breaker poster presentation.

“We are eager to present the full topline results from our Phase 3 ARTEMIS trial, which further support the evidence we first showed with our PALISADE and RAMSES studies that AR101-treated patients can expect to achieve a clinically meaningful level of desensitization,” said Daniel Adelman, M.D., Chief Medical Officer of Aimmune. “We believe that the positive results from our entire AR101 Phase 3 program, which we also will be discussing during the meeting, demonstrate that AR101 has a consistent benefit-risk profile. In addition, we are also pleased to be presenting data that underscore the real-world effects of living with peanut allergy as reported by patients themselves.”

https://www.biospace.com/article/releases/aimmune-to-present-ar101-data-at-european-academy-of-allergy-and-clinical-immunology-2019-congress/